These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
139 related articles for article (PubMed ID: 2283484)
1. CA 549 and SP2: new tumor markers in breast cancer. Torres M; Jiménez-Heffernan A; García A; Valverde A; Mateo A Int J Biol Markers; 1990; 5(2):97-8. PubMed ID: 2283484 [No Abstract] [Full Text] [Related]
2. Clinical use of tumor markers in the postoperative management of breast cancer patients: new concepts. Nicolini A; Carpi A; Ferrari P; Anselmi L Int J Biol Markers; 1997; 12(4):181-6. PubMed ID: 9582609 [No Abstract] [Full Text] [Related]
3. CEA, TPA and CA 15.3 in tissue and serum of breast cancer patients. Saccani Jotti G; Grassi C; Fontanesi M; Becchi G; Gion M Int J Biol Markers; 1992; 7(4):265-6. PubMed ID: 1491185 [No Abstract] [Full Text] [Related]
4. CA 15-3 in human breast cancer. Comparison with tissue polypeptide antigen (TPA) and carcinoembryonic antigen (CEA). Caponigro F; Iaffaioli RV; Pagliarulo C; De Placido S; Frasci G; Ungaro B; Matano E; Bianco AR Int J Biol Markers; 1990; 5(2):73-6. PubMed ID: 2283480 [TBL] [Abstract][Full Text] [Related]
5. CA 549 and SP2 in postoperative breast cancer patients. Comparison with CA 15.3, CEA and TPA. Torres M; Pacheco C; Valverde A; Rebollo AC; Moral A; Vallejo JA; Mateo A Int J Biol Markers; 1995; 10(2):94-9. PubMed ID: 7561245 [TBL] [Abstract][Full Text] [Related]
6. Serum (circulating) tumor markers for breast cancer. Hayes DF Recent Results Cancer Res; 1996; 140():101-13. PubMed ID: 8787054 [TBL] [Abstract][Full Text] [Related]
7. Impact of preoperative CA 15-3 levels in operable breast cancer. Comparison with tissue polypeptide antigen (TPA) and carcinoembryonic antigen (CEA). Iaffaioli RV; Caponigro F; Esposito G; Pagliarulo C; Deplacido S; Ungaro B; Bazzicalupo L; Frasci G; Bianco AR Int J Biol Markers; 1991; 6(1):21-4. PubMed ID: 1856513 [TBL] [Abstract][Full Text] [Related]
8. TPS in breast cancer--a comparative study with carcinoembryonic antigen and CA 15-3. van Dalen A Tumour Biol; 1992; 13(1-2):10-7. PubMed ID: 1589693 [TBL] [Abstract][Full Text] [Related]
9. [Circulating proteinic biomarkers and breast cancer]. Mathelin C; Koehl C; Rio MC Gynecol Obstet Fertil; 2006; 34(7-8):638-46. PubMed ID: 16876456 [TBL] [Abstract][Full Text] [Related]
10. Mucin-like cancer-associated antigen (MCA) compared with CA 15-3 in advanced breast cancer. Steger GG; Mader R; Derfler K; Moser K; Dittrich C Klin Wochenschr; 1989 Aug; 67(16):813-7. PubMed ID: 2796251 [TBL] [Abstract][Full Text] [Related]
11. [Tumor markers in metastatic breast carcinoma: correlations with clinical response]. Winer Y; Martini MC; Pastorino G; Moraglio L; Vallauri M; Brondi P; Brema F J Nucl Med Allied Sci; 1990; 34(4 Suppl):127-30. PubMed ID: 2092107 [No Abstract] [Full Text] [Related]
12. CA 549 as a marker in breast cancer. Dnistrian AM; Schwartz MK; Greenberg EJ; Smith CA; Dorsa R; Schwartz DC Int J Biol Markers; 1991; 6(3):139-43. PubMed ID: 1791307 [TBL] [Abstract][Full Text] [Related]
13. [Tumor markers in the diagnosis and prognosis of breast cancer]. Seliuzhitskiĭ IV; Skvortsov SV; Lytsar BN; Khomenko LP Klin Med (Mosk); 1993; 71(2):25-7. PubMed ID: 8046917 [TBL] [Abstract][Full Text] [Related]
14. Diagnosis of bone and liver metastases in breast cancer comparing tumor markers and imaging techniques. Zanco P; Rota G; Sportiello V; Borsato N; Ferlin G Int J Biol Markers; 1989; 4(2):103-5. PubMed ID: 2768888 [TBL] [Abstract][Full Text] [Related]
15. Evaluation of serum CA549, CA M26 and CA M29 levels in the post-operative follow-up of breast cancer patients. Nicolini A; Ferdeghini M; Colombini C; Carpi A J Nucl Med Allied Sci; 1990; 34(4):309-13. PubMed ID: 2090796 [TBL] [Abstract][Full Text] [Related]
16. Circulating CA 549 and other associated antigens in breast cancer patients. Pavesi F; Lotzniker M; Scarabelli M; Mauro E; Visconti G; Nicolato E; Moratti R Oncology; 1994; 51(1):18-21. PubMed ID: 8265097 [TBL] [Abstract][Full Text] [Related]
17. Mucin-like carcinoma-associated antigen (MCA) in breast cancer: clinical experience at the National Cancer Institute of Milan. Seregni E; Crippa F; Botti C; Bellotti MG; Bogni A; Pizzichetta M; Bombardieri E Int J Biol Markers; 1993; 8(2):124-9. PubMed ID: 8366295 [TBL] [Abstract][Full Text] [Related]
18. [Tumour markers of pancreatic cancer (tumour associated antigens)]. Groblewska M; Mroczko B; Szmitkowski M Pol Arch Med Wewn; 2005 Jun; 113(6):585-93. PubMed ID: 16454450 [No Abstract] [Full Text] [Related]
19. The early detection of disseminated (metastasized) breast cancer by serial tumour marker measurements. Jäger W Eur J Cancer Prev; 1993 Nov; 2 Suppl 3():133-9. PubMed ID: 8298443 [No Abstract] [Full Text] [Related]
20. The diagnostic value of CA 27-29, CA 15-3, mucin-like carcinoma antigen, carcinoembryonic antigen and CA 19-9 in breast and gastrointestinal malignancies. Frenette PS; Thirlwell MP; Trudeau M; Thomson DM; Joseph L; Shuster JS Tumour Biol; 1994; 15(5):247-54. PubMed ID: 7991985 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]